Zymeworks Management to Engage in Key Investor Conferences
VANCOUVER, British Columbia — Zymeworks Inc. (NASDAQ: ZYME), a pioneering biotechnology firm dedicated to developing avant-garde biotherapeutics aimed at addressing challenging diseases, has excitedly revealed its participation in several notable upcoming investor gatherings.
Details of the Conferences
Zymeworks' management team will engage in a series of one-on-one meetings and sessions at various conferences where they will share valuable insights about their ongoing projects and pipeline. Here are the key events they will attend:
UBS Global Healthcare Conference
On November 12, Zymeworks will take part in one-on-one meetings, providing an opportunity for investors to engage directly with management in Rancho Palos Verdes, CA.
Stifel 2024 Healthcare Conference
Scheduled for November 19, Zymeworks' team will participate in one-on-one meetings and a fireside chat, slated for 4:10 pm Eastern Time (ET) in New York, NY.
Jefferies London Healthcare Conference
Management will represent Zymeworks on November 20 and 21, focusing on one-on-one meetings as well as a fireside chat on November 20 at 2:30 pm Greenwich Mean Time in London.
Overview of Zymeworks Inc.
As a globally recognized clinical-stage biotechnology entity, Zymeworks is deeply committed to the discovery, development, and commercialization of novel biotherapeutics. The company aims to make a statistically significant difference in the lives of individuals suffering from difficult-to-treat cancers. With a solid foundation built upon complementary therapeutic technologies, their drug development framework allows precise engineering and creation of unique antibody-based treatment candidates.
One of Zymeworks' notable innovations is zanidatamab, a bispecific antibody designed to target HER2, crafted using their proprietary Azymetric™ technology. The company has forged strategic partnerships, granting exclusive rights for development and commercialization of zanidatamab with firms like BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited. This promising treatment is currently undergoing evaluation in numerous global clinical trials for its potential to be a best-in-class option for patients with HER2-positive cancers.
Pipeline Advancements and Future Prospects
The innovative company continues to develop a robust pipeline of proprietary product candidates, harnessing cutting-edge approaches in antibody-drug conjugates and multispecific antibody therapeutics. Currently, clinical trials for ZW171 and ZW191 are actively recruiting participants, showcasing Zymeworks' dedication to advancing treatments in areas of high unmet medical need.
Moreover, Zymeworks is navigating the regulatory landscape as a Biologics License Application (BLA) has been accepted by the U.S. Food and Drug Administration (FDA) for zanidatamab, specifically targeting previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer. This application has been granted Priority Review, highlighting the potential impact of this treatment in the medical field.
Contact Information
For investor inquiries, Shrinal Inamdar, Director of Investor Relations, is available at (604) 678-1388, or via email at ir@zymeworks.com.
For media inquiries, Diana Papove, Senior Director of Corporate Communications, can be reached at (604) 678-1388, or through email at media@zymeworks.com.
Frequently Asked Questions
What is Zymeworks known for?
Zymeworks is a biotechnology company specializing in the development of biotherapeutics to treat challenging diseases, particularly cancers.
What significant events will Zymeworks participate in?
Zymeworks will be part of notable investor conferences including UBS, Stifel, and Jefferies conferences, among others, focusing on their pipeline and management insights.
What innovative product is Zymeworks developing?
Zymeworks is working on zanidatamab, a bispecific antibody that targets HER2, currently undergoing clinical trials for patients with HER2-positive cancers.
How is zanidatamab being recognized in the industry?
It has received a Priority Review designation from the FDA, signifying its potential impact on treating specific types of cancers.
Who can I contact for more information?
Investor inquiries can be directed to Shrinal Inamdar at ir@zymeworks.com and media inquiries to Diana Papove at media@zymeworks.com.
